key: cord-0858056-t9mfc4ow
authors: Bhalla, Sheena; Bakouny, Ziad; Schmidt, Andrew L.; Labaki, Chris; Steinharter, John A.; Tremblay, Douglas A.; Awad, Mark M.; Kessler, Alaina J.; Haddad, Robert I.; Evans, Michelle; Busser, Fiona; Wotman, Michael; Curran, Catherine R.; Zimmerman, Brittney S.; Bouchard, Gabrielle; Jun, Tomi; Nuzzo, Pier V.; Qin, Qian; Hirsch, Laure; Feld, Jonathan; Kelleher, Kaitlin M.; Seidman, Danielle; Huang, Hsin-Hui; Anderson-Keightly, Heather M.; El Zarif, Talal; Abou Alaiwi, Sarah; Rosenbloom, Talia D.; Stewart, Penina S.; Galsky, Matthew D.; Choueiri, Toni K.; Doroshow, Deborah B.
title: Care Disruptions among Patients with Lung Cancer: A COVID-19 and Cancer Outcomes Study
date: 2021-07-16
journal: Lung Cancer
DOI: 10.1016/j.lungcan.2021.07.002
sha: 03618a267c0692c54ed7603a62e0f9cdecb8c0fc
doc_id: 858056
cord_uid: t9mfc4ow

INTRODUCTION: Patients with lung cancer (LC) are susceptible to severe outcomes from COVID-19. This study evaluated disruption to care of patients with LC during the COVID-19 pandemic. METHODS: The COVID-19 and Cancer Outcomes Study (CCOS) is a prospective cohort study comprised of patients with a current or past history of hematological or solid malignancies with outpatient visits between March 2 and March 6, 2020, at two academic cancer centers in the Northeastern United States (US). Data was collected for the three months prior to the index week (baseline period) and the following three months (pandemic period). RESULTS: 313 of 2365 patients had LC, 1578 had other solid tumors, and 474 had hematological malignancies. Patients with LC were not at increased risk of COVID-19 diagnosis compared to patients with other solid or hematological malignancies. When comparing data from the pandemic period to the baseline period, patients with LC were more likely to have a decrease in in-person visits compared to patients with other solid tumors (aOR 1.94; 95% CI, 1.46-2.58), but without an increase in telehealth visits (aOR 1.13; 95% CI 0.85-1.50). Patients with LC were more likely to experience pandemic-related treatment delays than patients with other solid tumors (aOR 1.80; 95% CI 1.13-2.80) and were more likely to experience imaging/diagnostic procedure delays than patients with other solid tumors (aOR 2.59; 95% CI, 1.46-4.47) and hematological malignancies (aOR 2.01; 95% CI, 1.02-3.93). Among patients on systemic therapy, patients with LC were also at increased risk for decreased in-person visits and increased treatment delays compared to those with other solid tumors. DISCUSSION: Patients with LC experienced increased cancer care disruption compared to patients with other malignancies during the early phase of the COVID-19 pandemic. Focused efforts to ensure continuity of care for this patient population are warranted.

Patients with cancer, specifically lung cancer (LC) are at markedly higher risk of severe outcomes from COVID-19 compared to the general population. [1] [2] [3] [4] This population is particularly susceptible to COVID-19 given their older age, smoking history, and pre-existing cardiopulmonary comorbidities. In many occurrences, as we previously reported, 5 the pandemic has resulted in significant disruption in cancer care, including decreased in-person visits, increased telehealth visits, and delays in treatment. The goal of this study was to evaluate the disruption to care of patients with LC during the COVID-19 pandemic.

The COVID-19 and Cancer Outcomes Study (CCOS) is a multicenter prospective cohort study comprised of adult patients with a current or past history of hematological malignancy or invasive solid tumor who participated in an outpatient medical oncology visit on the index week between March 2 and March 6, 2020, at the Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai in New York, New York (MSSM), and the Dana-Farber Cancer Institute in Boston, Massachusetts (DFCI). Data was abstracted manually by medical record review, and an electronic data capture platform was used to collect patient-, cancer-, and treatment-related variables during the 3 months prior to the index week (from December 2, 2019, referred to as the baseline period) and 3-month follow-up (until June 6, 2020, referred to as the pandemic period). Electronic data capture platform was used to ensure real-time data validation, and lead investigators conducted periodic quality checks to ensure consistency and accuracy in data collection.

The primary objective of this study was to examine the impact of COVID-19 on the delivery of cancer care among patients with LC as measured by the number of in-person outpatient visits, telehealth visits, and pandemic-related delays of oncologic care as recorded in the electronic medical record (EMR).

Pandemic-related delays were defined as any postponement in treatment, imaging, or diagnostic procedures due to COVID-19 infection, or provider/patient decision to limit patient's healthcare exposure as specifically documented in the EMR (further details provided in Supplementary Methods). Patients with either non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC) were included.

To evaluate the correlates of changes in cancer care delivery, multivariable logistic regression models, with listwise deletion for missing data, that included the following independent variables were computed: self-reported race and ethnicity (non-Hispanic White, Hispanic, non-Hispanic Black, or Other), cancer center (DFCI or MSSM), cancer status (metastatic/active, localized/stable, or no evaluable disease [NED]/complete remission, with the former referring to solid malignancies and the latter hematologic malignancies), and tumor type (LC, other solid tumor, or hematologic malignancies). For numbers of visits, per-patient differences in the numbers of visits in the pandemic period compared to the baseline period were used as the dichotomized dependent variables (any increase in telehealth visits and any decrease in in-person visits). Adjusted odds ratios (aORs) and 95% confidence intervals (CIs) were reported. For all logistic regression models, LC was used as the reference tumor type and the inverse of the model aOR and 95% CI were reported for all models. Median follow-up was determined using the inverse Kaplan-Meier method. All tests were two-tailed and considered statistically significant for p < 0.05. All analyses were done in the R statistical environment (v3.6.1).

The overall cohort included 2365 patients, of whom 313 (13.2%) had LC, 1578 (66.7%) had other solid tumors, and 474 (20.0%) had hematological malignancies (baseline characteristics summarized in Table  1 ). In terms of tumor status, 205 (65.5%) patients with LC had metastatic disease, 88 (28.1%) had local or locally advanced disease, and 15 (4.8%) had no evidence of disease. At the time of the index visit, 209 (66.8%) patients were receiving systemic therapy with a chemotherapy-containing regimen (28.1%, which included chemotherapy-immune checkpoint inhibitor combinations), targeted therapy (20.8%), or immune checkpoint inhibitor alone (12.3%), or other (2.6%). 

Patients with LC have experienced significant cancer care disruption due to the COVID-19 pandemic. 6, 7 In this prospective cohort study, patients with LC were at greater risk of COVID-19-related care disruption compared to patients with other malignancies; they experienced decreased in-person visits and increased treatment delays compared to patients with other solid tumors, as well as increased imaging/diagnostic delays compared to patients with both other solid and hematological malignancies. Among patients on systemic therapy during the index week, patients with LC were also at greater risk for decreased in-person visits and increased treatment delays compared to patients with other solid tumors. These findings may reflect the perception that patients were at increased risk of severe complications if they developed COVID-19 secondary to compromised pulmonary function or comorbidities prevalent in this population, leading to care alterations aimed at reducing infective risk. This perception aligns with the results of realworld studies which demonstrate that mortality from COVID-19 among patients with lung cancer early in the pandemic ranged from 25% to 33%. 1, 8, 9 This study examines the initial phase of the pandemic, when COVID-19 testing, treatment, and availability of telehealth was limited compared to today. Additionally, the non-lung cancer cohorts do not reflect the prevalence of these cancers in the general population and were based on available data from two US academic cancer centers. Even in view of these limitations, this study highlights that patients with LC were at increased risk for care disruption. These care alterations included increasing the duration between chemotherapy and immunotherapy cycles, as well as utilizing telehealth visits instead of inperson visits for patients on targeted oral therapy or active surveillance.

The consequences of delaying treatment, routine surveillance, and foregoing evidence-based cancer care among this high-risk population must be balanced against the competing risk of infection. Long-term effects of care change in patients undergoing lung cancer treatment or surveillance remain unknown, although alterations are unlikely to improve outcomes as most lead to fewer interactions with healthcare providers or decreased cancer-directed therapy. Literature detailing the impact of COVID-19 on new cancer diagnoses and prognosis is emerging, with fewer LC cases diagnosed during the pandemic period compared to the prior year and an increase in symptomatic and severe cases of LC diagnosed during the pandemic period. 10, 11 To date, no standard-of-care approach exists for treating patients with LC during the pandemic. Several organizations and groups of experts shared general recommendations for providers early in the pandemic. [12] [13] [14] The European Society of Medical Oncology (ESMO), for example, recommended prioritizing outpatient visits for individuals with new diagnosis of LC with disease-related symptoms or suspicion of clinical stage II-IV NSCLC and SCLC and those on current treatment. 13 Nonetheless, decisions must be individualized to each patient's specific circumstance and preferences and discussed within a multidisciplinary setting. 15 As the pandemic continues worldwide, providers must continually balance the risks of COVID-19 infection versus the risks of delaying cancer treatment and surveillance. It is essential to minimize delays in these evidence-based practices that are known improve patient outcomes. Prioritizing vaccination among patients is one essential step to resume continuity of care in this vulnerable population. odds ratios and 95% confidence intervals from the multivariable logistic regression model used to assess decrease in in-person visits during the pandemic period compared to the baseline period, increase in telehealth visits during the pandemic period compared to the baseline period, pandemic-related treatment and imaging delays, and COVID-19 diagnoses among patients with lung cancer compared to patients with other solid tumors and hematological malignancies Figure 2 : Forest Plot showing the adjusted odds ratios and 95% confidence intervals from the multivariable logistic regression model used to assess decrease in in-person visits during the pandemic period compared to the baseline period, increase in telehealth visits during the pandemic period compared to the baseline period, pandemic-related treatment and imaging delays, and COVID-19 diagnoses among patients with lung cancer on systemic therapy during the index week compared to patients with other solid tumors and hematological malignancies on systemic therapy during the index week. Pandemic-related delays were defined as any postponement in treatment, imaging, or diagnostic procedures due to COVID-19 infection, or provider/patient decision to limit patient's healthcare exposure as noted in the EMR by specific statements by physician or other healthcare provider indicating that delay was direct result of pandemic (i.e., "due to the pandemic," "due to COVID-19," etc). Pandemic-related delay was not inferred unless clear indication in medical record that change in care was a direct result of COVID-19. Pandemic related delays were classified as <1 week, 1-2 weeks, 2-4 weeks, and >4 weeks. Study investigators met weekly to discuss data collection process and ensure consistency in data and definitions across sites.

Definition of patient follow up included any patient contact as documented in the EMR (e.g., laboratory investigation, telephone encounter, and in-person visit). The EMR for both academic centers includes data from a broad healthcare network, encompassing many clinic/hospital sites and medical specialties.

Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study

Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China

Analyses of Risk, Racial Disparity, and Outcomes Among US Patients With Cancer and COVID-19 Infection

Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19)

Cancer Care Disparities during the COVID-19 Pandemic: COVID-19 and Cancer Outcomes Study

Changes in Lung Cancer Treatment as a Result of the Coronavirus Disease

Impact of COVID-19 in continuity of cancer treatment for lung cancer patients

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

COVID-19 in patients with lung cancer

Impact of COVID-19 Pandemic in the Diagnosis and Prognosis of Lung Cancer. 2020 World Conference on Lung Cancer Singapore

Cancer Screening Tests and Cancer Diagnoses During the COVID-19 Pandemic

Treatment Guidance for Patients With Lung Cancer During the Coronavirus 2019 Pandemic

Management and Treatment Adapted Recommendations in the COVID-19 Era: Lung Cancer

Management of Lung Cancer During the COVID-19 Pandemic

Integrated Survival Estimates for Cancer Treatment Delay Among Adults With Cancer During the COVID-19 Pandemic

Sheena Bhalla: conceptualization, methodology, investigation, writing -original draft, writing -review & editing. Ziad Bakouny: conceptualization, methodology, formal analysis, investigation, writingreview & editing. Andrew L. Schmidt: conceptualization, methodology, investigation, writing -review & editing. Chris Labaki: investigation, writing -review & editing. John A. Steinharter: investigation, writing -review & editing. Douglas A. Tremblay: investigation, writing -review & editing. Mark M. Awad: resources, writing -review & editing. Alaina J. Kessler: investigation, writing -review & editing. Robert I. Haddad: resources, writing -review & editing. Michelle Evans: investigation, writing -review & editing. Fiona Busser: investigation, writing -review & editing. Michael Wotman: investigation, writing -review & editing. Catherine R. Curran: investigation, writing -review & editing. Brittney S. Zimmerman: investigation, writing -review & editing. Gabrielle Bouchard: investigation, writing -review & editing. Tomi Jun: investigation, writing -review & editing . Pier V. Nuzzo: investigation, writing -review & editing. Qian Qin: investigation, writing -review & editing Laure Hirsch: investigation, writing -review & editing. Jonathan Feld: investigation, writing -review & editing. Kaitlin M. Kelleher: investigation

Anderson-Keightly: investigation, writing -review & editing. Talal El Zarif: investigation, writing -review & editing

Rosenbloom: investigation, writing -review & editing. Penina S. Stewart: investigation, writing -review & editing. Matthew D. Galsky: conceptualization, methodology, writing -review & editing. Toni K. Choueiri: conceptualization, methodology, writing -review & editing. Deborah B. Doroshow: conceptualization, methodology, investigation, writing -original draft